Squamous Cell Carcinoma Clinical Trials 2024

Squamous Cell Carcinoma Clinical Trials 2024

Squamous Cell Carcinoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in squamous cell carcinoma clinical trials today.

Squamous Cell Carcinoma Clinical Trials

Here are the 6 most popular medical studies for squamous cell carcinoma

Popular filter options for squamous cell carcinoma trials

Head And Neck Squamous Cell Carcinoma Clinical Trials

View 58 Head and Neck Squamous Cell Carcinoma medical studies.

SCC Clinical Trials

View 55 SCC medical studies.

Metastatic Squamous Cell Carcinoma Clinical Trials

View 100 metastatic squamous cell carcinoma medical studies.

P16 Positive Clinical Trials

View 13 p16 positive medical studies.

PD-L1 Positive Clinical Trials

View 8 PD-L1 positive medical studies.

Phase 3 Squamous Cell Carcinoma Clinical Trials

View 100 phase 3 squamous cell carcinoma medical studies.

Squamous Cell Carcinoma Clinical Trials With No Placebo

View 100 squamous cell carcinoma medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to squamous cell carcinoma

What are the top hospitals conducting squamous cell carcinoma research?

Hospitals at the forefront of squamous cell carcinoma research are making significant strides in understanding and treating this form of cancer. In Saint Louis, the Washington University School of Medicine is leading the charge with 11 active clinical trials dedicated to squamous cell carcinoma. While they have only conducted one trial historically, their commitment since recording their first study in 2007 demonstrates a promising future for patients battling this disease. The Memorial Sloan Kettering Cancer Center in New york has also made notable contributions, currently undertaking five ongoing clinical trials and having completed seven previous trials focusing on squamous cell carcinoma since launching their initial investigation in 2007.

Meanwhile, in Houston's esteemed University of Texas MD Anderson Cancer Center, researchers are actively conducting four clinical trials aimed at better understanding and combating squamous cell carcinoma. Despite having just two previous studies under their belt since embarking on this research path back in 2004, the institution's dedication is evident as they continue to explore new treatment options for patients affected by this condition.

Further emphasizing the importance of these efforts is Boston's Dana Farber Cancer Institute where another four current squamous cell carcinoma clinical trials are underway alongside four completed studies dating back to their inaugural trial in 2006—a testament to their continuous pursuit of innovation within oncology research.

Rounding out our list is Charleston's Medical University of South carolina, which may have fewer active and historical clinical trials compared to its counterparts but still plays a crucial role. With three ongoing studies focused on squamous cell carcinoma and one past trial recorded from as recently as 2006, they contribute valuable insights into improving patient outcomes and expanding our knowledge about this particular type of cancer.

These top hospitals exemplify unwavering dedication toward unraveling the mysteries surrounding squamous cell carcinoma; each step taken brings us closer to more effective treatments that can improve lives and ultimately defeat this formidable foe.

Which are the best cities for squamous cell carcinoma clinical trials?

When it comes to squamous cell carcinoma clinical trials, several cities emerge as prominent hubs for research and development. New york leads the pack with 25 active studies exploring treatments like Cemiplimab, Definitive Hypofractionation, and Pembrolizumab 200 mg. Saint Louis closely follows with 22 ongoing trials investigating interventions such as Palbociclib, Pembrolizumab, and Pyrimethamine. Boston also plays a significant role in this field with 17 active studies focusing on therapies like Pembrolizumab and Cemiplimab. Additionally, Houston (16 trials) and Los Angeles (14 trials) contribute to the advancement of knowledge through their respective investigations into potential treatment options for squamous cell carcinoma.

Which are the top treatments for squamous cell carcinoma being explored in clinical trials?

In the realm of squamous cell carcinoma, clinical trials are exploring various treatment options that show promise. Leading the pack is pembrolizumab, currently involved in nine active trials dedicated to this specific type of cancer. Since its first listing in 2014, it has demonstrated potential through eight all-time squamous cell carcinoma trials. Alongside pembrolizumab, durvalumab has caught researchers' attention with three ongoing trials and one all-time trial since being introduced just last year in 2020. Additionally, cetuximab exhibits significant potential with three active and nine all-time squamous cell carcinoma trials since its debut back in 2008. These treatments provide hope for patients battling squamous cell carcinoma as research progresses towards finding more effective solutions to combat this disease.

What are the most recent clinical trials for squamous cell carcinoma?

Recent clinical trials for squamous cell carcinoma offer new hope and potential treatment options for patients. These trials include the evaluation of INCB099280 Dose 1, which has entered Phase 2 and shows promise in combating this type of cancer. Additionally, a combination therapy involving GB1211 and Pembrolizumab is being studied to assess its effectiveness against squamous cell carcinoma. The Reduce Dose without Concurrent Chemotherapy Rapid Responder trial aims to determine if reducing the dose of chemotherapy while maintaining efficacy can benefit patients with this condition. Other ongoing studies such as Single Cohort and Arm 1 are also exploring innovative approaches to better understand and treat squamous cell carcinoma. These advancements highlight the commitment of researchers towards improving outcomes for individuals affected by this disease.

What squamous cell carcinoma clinical trials were recently completed?

A recent completion of a clinical trial brings encouraging news for patients with squamous cell carcinoma. The University of Arizona led an investigation into the efficacy of injecting TVEC directly into target lesions during weeks 1-2. This ground-breaking trial, completed in August 2018, highlights the ongoing efforts to improve treatment options and outcomes for individuals battling this particular type of skin cancer. Though more research is needed, such advancements offer hope and potential breakthroughs in the fight against squamous cell carcinoma.